← SynDRA
LINSITINIB
SynDRA canonical compound SYN0021745 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | INSR |
|---|
| Mechanism of action | IGF-1 inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- IGF-1 inhibitor
- IGF1R INHIBITOR
- Insulin-like growth factor I receptor inhibitor
- INSR INHIBITOR
- Insulin receptor inhibitor
Cross-references
Synonyms
- ASP-7487
- LINSITINIB (OSI-906)
- OSI-906
- OSI-906AA
- OSI906
- OSI 906
- Linsitinib(OSI-906)
- OSI-906 (Linsitinib)
- UNII-15A52GPT8T
- Kinome_3532
- 3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutan-1-ol
- 15A52GPT8T
- CHEMBL1091644
- MMV676605
- cis-3-[8-Amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methylcyclobutanol
- C26H23N5O
- cis-3-(8-amino-1-(2-phenyl-7-quinolinyl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
- Linsitinib [USAN:INN]
- OSI906/Linsitinib/
- (1r,3r)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol.
- Linsitinib [USAN]
- CIS-3-(8-AMINO-1-(2-PHENYLQUINOLIN-7-YL)IMIDAZO(1,5-A)PYRAZIN-3-YL)-1-METHYLCYCLOBUTAN-1-OL
- Cis-3-(8-Amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutan-1-ol
- Linsitinib; OSI-906
- LINSITINIB [INN]
- Linsitinib (USAN/INN)
- Linsitinib (OSI-906)
- LINSITINIB [WHO-DD]
- MLS006010304
- SCHEMBL400369
- SCHEMBL400734
- SCHEMBL400735
- GTPL7423
- CHEMBL1996234
- SCHEMBL10255925
- CHEBI:91402
- EX-A719
- BCPP000137
Look up LINSITINIB in the interactive SynDRA portal →